The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Dara-VRd in multiple myeloma with high-risk cytogenetics: insights from the PERSEUS trial
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the PERSEUS trial (NCT03710603), which established daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd) as a new standard of care (SoC) for transplant-eligible multiple myeloma (MM). While patients with high-risk cytogenetics showed improved outcomes with this regimen, an unmet treatment need remains for this group. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen, Sanofi, Regeneron, Celgene, Menarini, Takeda, GSK, BMS, Janssen, Beigene, Swixx, Astra Zeneca.
